Home › Companies › Lineage Cell Therapeutics, Inc. › 2025-2026

Lineage Cell Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Lineage Cell Therapeutics, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.

9Ballot items
100Asset managers
332Fund votes
2026-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Lineage Cell Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Lineage Cell Therapeutics, Inc.

These tallies are Lineage Cell Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Lineage Cell Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Michael H. Mulroy	90,383,337	--	--	1,201,448	73,917,854	Majority: yes
Elect Director: Dipti Amin	90,428,362	--	--	1,156,423	73,917,854	Majority: yes
Elect Director: Deborah Andrews	90,328,622	--	--	1,256,163	73,917,854	Majority: yes
Elect Director: Angus C. Russell	90,464,859	--	--	1,119,926	73,917,854	Majority: yes
Elect Director: Neal C. Bradsher	90,514,702	--	--	1,070,083	73,917,854	Majority: yes
Elect Director: Brian M. Culley	89,917,990	--	--	1,666,795	73,917,854	Majority: yes
Elect Director: Anula Jayasuriya	90,549,317	--	--	1,035,468	73,917,854	Majority: yes
Proposal 2: Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:	163,825,928	659,670	1,017,041	--	--	Majority: yes
Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:	88,328,168	2,600,932	655,685	--	73,917,854	Passed

This meeting is also recorded here as 2026-06-09; both records come from the same filing, so the date should be checked against it.

Source: Lineage Cell Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.

How asset managers voted at the Lineage Cell Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 100 asset managers that disclosed a Lineage Cell Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 6 wordings of this item as funds reported it.

97% Passed · of votes cast

FOR 97%

FOR: 88,328,168AGAINST: 2,600,932

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”): 88,328,168 for, 2,600,932 against — passed, per its Form 8-K filed 2026-06-12 (Item 5.07). Of all 249,298,295 outstanding shares: 35% for, 1% against (36% of the company cast a for/against vote).

The 100 asset managers below cast 99.9% of the shares they voted on this item FOR (18,511,111 for, 187 against).

FOR 99.3%

FOR: 18,511,111 (99.3%)AGAINST: 187 (0.0%)ABSTAIN: 3 (0.0%)NOT VOTED: 130,200 (0.7%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	7,905,585	10	3	For
RAFFLES ASSOCIATES LP	4,101,438	0	0	For
BlackRock	2,357,978	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,129,570	0	0	For
Fidelity	798,749	0	0	For
Northern Trust	490,988	0	0	For
MARSHALL WACE, LLP	390,166	0	0	For
State Street	324,211	0	0	For
Informed Momentum Co LLC	217,646	0	0	For
STIFEL NICOLAUS & CO INC \MO\	147,113	0	0	For
Donor Advised Charitable Giving, Inc.	0	0	0	Not Voted
Renaissance	118,726	0	0	For
CIBC Capital Markets (Europe) S.A.	47,050	0	0	For
CIBC WORLD MARKET INC.	47,050	0	0	For
Goldman Sachs	34,401	0	0	For
TRUST CO OF TOLEDO NA /OH/	33,795	0	0	For
MELLON INVESTMENTS Corp	29,720	0	0	For
Voleon Capital Management LP	25,363	0	0	For
Two Sigma	22,206	0	0	For
Fifth Third Wealth Advisors LLC	20,000	0	0	For
GC Wealth Management RIA, LLC	18,713	0	0	For
Founders Capital Management	16,000	0	0	For
WELLS FARGO CLEARING SERVICES, LLC	15,011	0	0	For
Charles Schwab	13,381	0	0	For
Fisher Asset Management, LLC	13,096	0	0	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

2. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,464,859WITHHELD: 1,119,926

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Angus C. Russell”): 90,464,859 for, 1,119,926 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.5% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,494,089 for, 0 against).

FOR 99.8%

FOR: 9,494,089 (99.8%)ABSTAIN: 18,062 (0.2%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,707,257	18,062	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

3. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,549,317WITHHELD: 1,035,468

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 90,549,317 for, 1,035,468 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.5% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,512,147 for, 0 against).

FOR 99.9%

FOR: 9,512,147 (100.0%)ABSTAIN: 3 (0.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,725,315	3	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

4. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 89,917,990WITHHELD: 1,666,795

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian M. Culley”): 89,917,990 for, 1,666,795 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.7% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,494,087 for, 0 against).

FOR 99.8%

FOR: 9,494,087 (99.8%)ABSTAIN: 18,064 (0.2%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,707,255	18,064	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

5. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,328,622WITHHELD: 1,256,163

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Andrews”): 90,328,622 for, 1,256,163 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.6% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,494,089 for, 0 against).

FOR 99.8%

FOR: 9,494,089 (99.8%)ABSTAIN: 18,062 (0.2%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,707,257	18,062	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

6. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,428,362WITHHELD: 1,156,423

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Dipti Amin”): 90,428,362 for, 1,156,423 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.5% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,512,146 for, 0 against).

FOR 99.9%

FOR: 9,512,146 (100.0%)ABSTAIN: 4 (0.0%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,725,314	4	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

7. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,383,337WITHHELD: 1,201,448

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 90,383,337 for, 1,201,448 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.5% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,494,089 for, 0 against).

FOR 99.8%

FOR: 9,494,089 (99.8%)ABSTAIN: 18,062 (0.2%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,707,257	18,062	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

8. To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 90,514,702WITHHELD: 1,070,083

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 90,514,702 for, 1,070,083 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 36% for, 0.5% withheld (37% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (9,494,089 for, 0 against).

FOR 99.8%

FOR: 9,494,089 (99.8%)ABSTAIN: 18,062 (0.2%)

Largest asset managers voting on “To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respecti” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	7,707,257	18,062	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

9. To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 163,825,928AGAINST: 659,670

Lineage Cell Therapeutics, Inc.’s own tally for this item (“Proposal 2: Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:”): 163,825,928 for, 659,670 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 249,298,295 outstanding shares: 66% for, 0.3% against (66% of the company cast a for/against vote).

The 10 asset managers below cast 99.9% of the shares they voted on this item FOR (9,512,148 for, 1 against).

FOR 99.9%

FOR: 9,512,148 (100.0%)AGAINST: 1 (0.0%)

Largest asset managers voting on “To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our ” at Lineage Cell Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	7,725,316	1	For
BlackRock	1,143,785	0	For
Fidelity	607,818	0	For
Goldman Sachs	9,748	0	For
BRIDGEWAY FUNDS INC	9,600	0	For
Charles Schwab	6,569	0	For
Lincoln Financial	4,300	0	For
John Hancock	3,995	0	For
Guggenheim	747	0	For
Victory Capital	270	0	For

Largest Lineage Cell Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Lineage Cell Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 249,298,295 shares outstanding at the time of that meeting.

Top Lineage Cell Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	3.17%
2	RAFFLES ASSOCIATES LP	1.65%
3	BlackRock	0.95%
4	GEODE CAPITAL MANAGEMENT, LLC	0.45%
5	Fidelity	0.32%
6	Northern Trust	0.20%
7	MARSHALL WACE, LLP	0.16%
8	State Street	0.13%
9	Informed Momentum Co LLC	0.09%
10	STIFEL NICOLAUS & CO INC \MO\	0.06%

Reported Lineage Cell Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Lineage Cell Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Broadwood Partners, L.P.	20.07%	DEF14A
Neal C. Bradsher	20.07%	DEF14A
Vanguard Group	3.87%	13F
Brian M. Culley	3.53%	DEF14A
Millennium Management	2.23%	13F
BlackRock	1.55%	13F
Geode Capital	1.01%	13F
George A. Samuel III	1.00%	DEF14A
Renaissance Technologies	0.85%	13F
Morgan Stanley	0.80%	13F

Percentages above are of 249,298,295 shares outstanding, as reported by Lineage Cell Therapeutics, Inc. on its Form 10-Q dated 2026-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lineage Cell Therapeutics, Inc.’s 10-Q dated 2026-05-08. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Lineage Cell Therapeutics, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 100 asset managers reported how they voted on 9 ballot items in their SEC Form N-PX filings, covering 332 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — the proposal passed with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Lineage Cell Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.

Lineage Cell Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).